Skip to content

Study · In vitro (cells) · 1995

3 results

Regulation of insulin-like growth factor-binding protein-4 in human endometrial stromal cell cultures: evidence for ligand-induced proteolysis.

Irwin JC, Dsupin BA, Giudice LC

The Journal of clinical endocrinology and metabolism1 Feb 1995Cited by 24 (Europe PMC)

PMID7531715 (opens in a new tab)DOI10.1210/jcem.80.2.7531715 (opens in a new tab)PepBankPUB-07531715
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In human endometrial stromal cell cultures, LR3-IGF-I increased detectable IGFBP-4 at all concentrations tested.

    In plain wordsIn human endometrial cells in the lab, LR3-IGF-I raised the detectable level of IGFBP-4 at every concentration tested.

    Peptide
    IGF-1 LR3
    Outcome
    IncreaseDetectable IGFBP-4 level
    Study

    humann: not reported in source

    Human endometrial stromal cell cultures
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    LR3-IGF-I, which has 1000-fold lower binding affinity than IGF-I, increased detectable IGFBP-4 at all concentrations tested.
    1 context sentence
    Summary · context
    The present study investigates the regulation of IGFBP-4 levels by insulin-like growth factor (IGF) peptides in human endometrial stromal cell cultures.
  2. 02LabIn vitro (cells)Mechanism

    In human endometrial stromal cultures, des-(1-3)-IGF-I increased detectable IGFBP-4 at low concentrations.

    In plain wordsIn cells, low concentrations of des-(1-3)-IGF-I increased detectable IGFBP-4.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseDetectable IGFBP-4 at low concentrations
    Study

    humann: not reported in source

    Endometrial stromal cell cultures
    Outcome group
    Receptor activity and mechanism · Reproductive and sexual health
    Studied dose
    0.1-10 ng/mLAs given in this study (human).

    Source sentences

    Summary
    Des-(1-3)-IGF-I, whose affinity for IGFBP-4 is 30-fold lower than that of IGF-I, increased detectable IGFBP-4 at low concentrations (0.1-10 ng/mL), but reduced its levels at 100 ng/mL, consistent with the significant binding to IGFBP-4 at this concentration.
    1 context sentence
    Summary · context
    The present study investigates the regulation of IGFBP-4 levels by insulin-like growth factor (IGF) peptides in human endometrial stromal cell cultures.
  3. 03LabIn vitro (cells)Mechanism

    In human endometrial stromal cultures, des-(1-3)-IGF-I reduced detectable IGFBP-4 at high concentration.

    In plain wordsIn cells, a high concentration of des-(1-3)-IGF-I reduced detectable IGFBP-4.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    DecreaseDetectable IGFBP-4 at high concentration
    Study

    humann: not reported in source

    Endometrial stromal cell cultures
    Outcome group
    Receptor activity and mechanism · Reproductive and sexual health
    Studied dose
    100 ng/mLAs given in this study (human).

    Source sentences

    Summary
    Des-(1-3)-IGF-I, whose affinity for IGFBP-4 is 30-fold lower than that of IGF-I, increased detectable IGFBP-4 at low concentrations (0.1-10 ng/mL), but reduced its levels at 100 ng/mL, consistent with the significant binding to IGFBP-4 at this concentration.
    1 context sentence
    Summary · context
    The present study investigates the regulation of IGFBP-4 levels by insulin-like growth factor (IGF) peptides in human endometrial stromal cell cultures.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 3 to 4Current

    21 Oct 2026, 13:52 UTC

    The same notice was added 2 times, first on 21 Oct 2026, 12:50 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  2. Version 2

    13 Oct 2026, 21:44 UTC

    Study results updated

  3. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.